Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials
Autor: | George I. Papakostas, Yongcai Mao, Sara Larsson, Dayong Li, Henning F Andersen, Susan G. Kornstein |
---|---|
Rok vydání: | 2009 |
Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Venlafaxine Thiophenes Citalopram Duloxetine Hydrochloride Severity of Illness Index Drug Administration Schedule law.invention Young Adult symbols.namesake chemistry.chemical_compound Double-Blind Method Randomized controlled trial Norepinephrine reuptake inhibitor law Internal medicine Outcome Assessment Health Care medicine Humans Escitalopram Duloxetine Psychiatry Fisher's exact test Aged Randomized Controlled Trials as Topic Aged 80 and over Psychiatric Status Rating Scales Depressive Disorder Major Venlafaxine Hydrochloride Middle Aged Cyclohexanols medicine.disease Psychiatry and Mental health chemistry symbols Major depressive disorder Female Neurology (clinical) Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
Zdroj: | CNS Spectrums. 14:326-333 |
ISSN: | 2165-6509 1092-8529 |
Popis: | Introduction: Recent data suggest that escitalopram may be more effective in severe depression than other selective serotonin reuptake inhibitors.Methods: Individual patient data from four randomized, double-blind comparative trials of escitalopram versus a serotonin/norepinephrine reuptake inhibitor (SNRI) (two trials with duloxetine and two with venlafaxine extended release) in outpatients (18–85 years of age) with moderate-to-severe major depressive disorder were pooled. The primary efficacy parameter in all four trials was mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) score.Results: Significantly fewer escitalopram (82/524) than SNRI (114/527) patients prematurely withdrew from treatment due to all causes (15.6% vs. 21.6%, Fisher Exact: P=.014) and adverse events (5.3% vs. 12.0%, Fisher Exact: P P P Conclusion: This pooled analysis indicates that escitalopram is at least as effective as the SNRIs (venlafaxine XR and duloxetine), even in severe depression, and escitalopram treatment was better tolerated. |
Databáze: | OpenAIRE |
Externí odkaz: |